156 related articles for article (PubMed ID: 15084863)
21. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
Evans ME
Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
[TBL] [Abstract][Full Text] [Related]
22. Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.
Garrison MW
J Antimicrob Chemother; 2003 Sep; 52(3):503-6. PubMed ID: 12917240
[TBL] [Abstract][Full Text] [Related]
23. Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.
White RL; Enzweiler KA; Friedrich LV; Wagner D; Hoban D; Bosso JA
Diagn Microbiol Infect Dis; 2002 Jul; 43(3):207-17. PubMed ID: 12106954
[TBL] [Abstract][Full Text] [Related]
24. The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci.
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 1996 May; 25(1):47-51. PubMed ID: 8831045
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, ofloxacin and levofloxacin.
Fuchs PC; Barry AL; Brown SD
J Antimicrob Chemother; 1997 May; 39(5):671-2. PubMed ID: 9184374
[No Abstract] [Full Text] [Related]
26. Comparative activities of ciprofloxacin and levofloxacin against Streptococcus pneumoniae in an In vitro dynamic model.
Zinner SH; Simmons K; Gilbert D
Antimicrob Agents Chemother; 2000 Mar; 44(3):773-4. PubMed ID: 10681356
[TBL] [Abstract][Full Text] [Related]
27. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
Loza E; Cantón R; Pascual A; Tubau F; Morosini MI; Almaraz F; Perea E; Martín R; Jones RN; Baquero F
Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
[TBL] [Abstract][Full Text] [Related]
28. Emergence of penicillin-resistant Streptococcus pneumoniae ocular infections.
Penland RL; Wilhelmus KR
Cornea; 1998 Mar; 17(2):135-40. PubMed ID: 9520187
[TBL] [Abstract][Full Text] [Related]
29. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
Visalli MA; Jacobs MR; Appelbaum PC
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703
[TBL] [Abstract][Full Text] [Related]
30. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.
Lafredo SC; Foleno BD; Fu KP
Chemotherapy; 1993; 39(1):36-9. PubMed ID: 8383031
[TBL] [Abstract][Full Text] [Related]
31. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
32. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.
Madaras-Kelly KJ; Demasters TA
Diagn Microbiol Infect Dis; 2000 Aug; 37(4):253-60. PubMed ID: 10974576
[TBL] [Abstract][Full Text] [Related]
33. Streptococcus pneumoniae killing rate and post-antibiotic effect of levofloxacin and ciprofloxacin.
Fuchs PC; Barry AL; Brown SD
J Chemother; 1997 Dec; 9(6):391-3. PubMed ID: 9491837
[TBL] [Abstract][Full Text] [Related]
34. A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group.
Hoban DJ; Bouchillon SK; Karlowsky JA; Johnson JL; Butler DL; Miller LA; Poupard JA
Antimicrob Agents Chemother; 2000 Nov; 44(11):3008-11. PubMed ID: 11036014
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility testing of Streptococcus pneumoniae and Viridans streptococcal isolates against: quinolones, oxazolidinones and glycopeptides.
Băncescu G; Neagu AS; Radu-Popescu M; Nica M; Dascălu A; Nistor I; Bărbuceanu SF; Băncescu A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(1):286-90. PubMed ID: 23077910
[TBL] [Abstract][Full Text] [Related]
36. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae.
Bauernfeind A
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():77-82. PubMed ID: 10404343
[TBL] [Abstract][Full Text] [Related]
38. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.
Graves A; Henry M; O'Brien TP; Hwang DG; Van Buskirk A; Trousdale MD
Cornea; 2001 Apr; 20(3):301-5. PubMed ID: 11322420
[TBL] [Abstract][Full Text] [Related]
39. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
Wise R; Andrews JM
J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
[TBL] [Abstract][Full Text] [Related]
40. Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
Black J; Moland ES; Chartrand SA; Thomson KS
Diagn Microbiol Infect Dis; 2001 Mar; 39(3):195-7. PubMed ID: 11337189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
